OTC: HNSBF - Hansa Biopharma AB (publ)

Yield per half year: +2.39%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Hansa Biopharma AB (publ)

Extended chart Simple chart
Financial Markets by TradingView

About Hansa Biopharma AB (publ)

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments with rare immunological conditions using its proprietary enzyme technology platform. The company's lead drug candidate is Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy.

more details
The company has a preclinical research collaboration agreement with argenx BV to evaluate the potential of combining imlifidase and efgartigimod to potentially be used in the acute and chronic setting of autoimmune diseases and transplantation. It also has a collaboration with Genethon to develop imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.hansabiopharma.com
Цена ао 3
Change price per 3 month: +6.01% (2.83)
Change price per half year: +2.39% (2.93)
Change price per year: +2.39% (2.93)
Change price per 3 year: -67.57% (9.25)
Change price per 5 year: -64.03% (8.34)
Change price per year to date: +6.01% (2.83)
All parameters

Underestimation

Title Value Grade
P/S 12.2 1
P/BV -3.55 0
P/E 0 0
EV/EBITDA -4.48 0
Total: 3.5

Efficiency

Title Value Grade
ROA, % -14.6 0
ROE, % 70.78 10
Total: 3.33

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -1.75 10
Total: 9.6

Growth impulse

Title Value Grade
Yield Revenue, % 267.39 10
Yield Ebitda, % -80.32 0
Yield EPS, % -82.95 0
Total: 2
More

Institutions Volume Share, %
SPDR Portfolio Developed World ex-US ETF 115184 0.22
SPDR (R) Idx Shares-SPDR (R) S&P (R) International Small Cap ETF 30740 0.06
SPDR (R) Portfolio Europe ETF 611 0



Head Job title Payment Year of birth
Mr. Søren Tulstrup M.Sc President & CEO 16.12M 1965 (60 years)
Dr. Christian Kjellman Senior VP & COO N/A 1967 (58 years)
Dr. Hitto Kaufmann Ph.D. Chief Scientific Officer N/A 1971 (54 years)
Ms. Eva-Maria Joed Vice President of Finance & Administration N/A 1969 (56 years)
Mr. Klaus Sindahl VP & Head of Investor Relations N/A
Ms. Anne Säfström Lanner Senior VP & Chief Human Resources Officer N/A 1969 (56 years)
Mr. Emanuel Björne VP & Head of Business Development N/A 1973 (52 years)
Dr. Lena Winstedt Head of Science N/A 1969 (56 years)
Ms. Vincenza Nigro M.B.A. VP & Head of Medical Affairs N/A
Mr. C. Evan Ballantyne Chief Financial Officer N/A 1960 (65 years)

Address: Sweden, Lund, ScheelevAegen 22 - open in Google maps, open in Yandex maps
Website: https://www.hansabiopharma.com